AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02643433 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-Rubella combined vaccine(MR)
Description: 0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
Study NCT02643433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-Rubella combined vaccine(MR)
Description: 0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
Study NCT02643433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis alive vaccine(JE)
Description: 0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
Study NCT03446092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness for health
Description: A course of mindfulness using the mindfulness for health programme.
Study NCT03163719 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CK and Lactate dosages
Description: A patient consulting the emergency department for suspected seizure will have an usual blood test at the admission in this context with notably ionogram, fasting glucose, venous gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay. The Creatine kinase dosage will be collected in the usual way as a tube bottom. As recommended by the French Society of Neurology, a new sample will be collected at 4 hours of seizure for a dosage of Creatine kinase. The determination of the lactates will be based on a tube bottom.
Study NCT01073163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine at 90 mg/m\^2 IV on Days 1 and 2 of a 28-day cycle.
Study NCT01073163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab at 375 mg/m\^2 IV on Day 1 of a 28-day cycle.
Study NCT00940888 — intervention group
Intervention type: DEVICE
Intervention: SJ4 connector and RV high voltage SJ4 lead
Description: Standard of care implantation of SJ4 device system
Study NCT01228656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate + salicylic acid
Description: Dermatologic ointment applied once a day.
Study NCT01228656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate
Description: Dermatologic ointment applied once a day
Study NCT03977987 — intervention group
Intervention type: DRUG
Intervention: nucleos(t)ide analogue
Description: Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
Study NCT01808937 — intervention group
Intervention type: OTHER
Intervention: Morphea
Study NCT01275989 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Ear acupuncture
Study NCT03733353 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: Placebo
Study NCT03733353 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral tablet
Description: Placebo
Study NCT01275989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ear acupuncture
Study NCT01275989 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ear acupuncture
Study NCT04034212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Singing for Lung Health group attendance
Description: Singing for Lung Health is a group singing intervention designed for people with chronic lung diseases. Participants would attend weekly sessions lasting 1 hour.
Study NCT02489448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments.
Study NCT04394156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cognitive intervention
Description: See the information provided in the experimental arm description.
Study NCT01971567 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIRREM
Study NCT01971567 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HIRREM
Study NCT03834025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1 Condition 1
Description: Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation.
Study NCT03834025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1 Condition 2
Description: Providers assigned to this condition will be sent recruitment materials that include an additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2).
Study NCT03834025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1 Condition 3
Description: Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3).
Study NCT03834025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1 Condition 4
Description: Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4).
Study NCT03834025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 1
Description: Providers who enroll in the study and are assigned to this condition will be in this group. Other than the opportunity to participate in a learning collaborative, participants receive no compensation.
Study NCT01384162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0029
Description: ICV infusion
Study NCT02224703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Study NCT03834025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 2
Description: Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.
Study NCT02224703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Study NCT03149042 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA
Description: Diagnostic Test
Study NCT04061876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants began oral administration of ruxolitinib at 5 mg QD;Methylprednisolone: 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
Study NCT04061876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 3 days, then taper according to the clinical response. 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
Study NCT04061876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 3 days, then taper according to the clinical response. 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
Study NCT03232918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half dose Oxytocin
Description: Patients randomized to the half dose oxytocin group will have the oxytocin infusion reduced to 50 % prior to placement of combined spinal epidural for labor analgesia
Study NCT06256081 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hear Glue ear application
Description: Hear Glue ear is an application used on phones, ipads, tablets or computers which provides free information, songs, audiobooks, games and a home hearing screening game.
Study NCT06256081 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hear Glue ear application
Description: Hear Glue ear is an application used on phones, ipads, tablets or computers which provides free information, songs, audiobooks, games and a home hearing screening game.
Study NCT03478449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node sorting for pathological examination
Description: In this study, intervention methods include two kinds of lymph node sorting for pathological examination in gastric cancer samples after curative surgery. One is the fine sorting lymph nodes, representing the lymph nodes should be sorted one by one from the tissues around the stomach, celiac axis, and the main brunches of celiac axis. The other is the group sorting lymph nodes, representing the lymph nodes should be simply sorted in the soft tissues around the stomach, celiac axis, and the main brunches of celiac axis.
Study NCT04848324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Hydrodissection
Description: The median nerve was examined by US at the scaphoid-pisiform level of the inlet of carpal tunnel. The hydrodissection was achieved by a total volume of 3 mL (1 mL of triamcinolone and 2 mL of saline) in the intervention group based on a study identifying median nerve hydrodissection with this volume. Half of the total volume (1.5 mL ) was delivered via the in-plane ulnar approach and the other half (1.5 mL) via the in-plane median approach to create a fluid plane along the nerve.
Study NCT04848324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: 1 mL of triamcinolone was delivered via the in-plane ulnar approach
Study NCT02042027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamunex-C
Description: Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)
Study NCT01375998 — intervention group
Intervention type: DRUG
Intervention: EE20/DRSP(YAZ, BAY86-5300)
Description: Patients in daily life treatment receiving YAZ for dysmenorrhea.
Study NCT05431218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol Liquid
Description: daily single dose of the drug in the first half of the day in an individually selected dose for 3 months
Study NCT00605332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inferior vena cava filter
Description: Crux Biomedical IVC Filter
Study NCT02833324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education regarding ambulation
Description: The participants will be educated on the importance of postoperative ambulation during the recovery period.
Study NCT02833324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education regarding ambulation
Description: The participants will be educated on the importance of postoperative ambulation during the recovery period.
Study NCT02833324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulation reminder alarms
Description: Participants in the intervention arm will receive 5 daily alarms to prompt them to ambulate. Alarms will be set to ring at 9am, 11am, 2pm, 5pm and 9pm. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
Study NCT02833324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
Study NCT02833324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
Study NCT03290053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: SonoVue-infusion over 1 hour
Study NCT03290053 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium chloride
Description: Placebo
Study NCT03290053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound
Description: Transcranial ultrasound aimed at the blockage
Study NCT03290053 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Ultrasound
Description: Placebo - machine is attached, but not active
Study NCT04659330 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online education (BdandMe) for injection technique
Description: patients were referred to the relevant modules on BD and Me™ (for online education)
Study NCT04659330 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 4mm needles
Description: Providing a supply of needles for single use of 4mm insulin injection needle.
Study NCT01860326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Capsules supplied as open labeled bulk medication in 10-unit blister packages
Study NCT03869177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation support program
Description: The IFIP intervention consists of the following elements:~I. Clinical interventions 1.1 A basic level of family involvement and support 1.2 Family psychoeducation in single-family groups~II. Implementation interventions 2.1 Training and guidance of health care personnel 2.2 A family coordinator 2.3 Other implementation measures
Study NCT01777165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-719
Description: 1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
Study NCT01777165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study NCT02118649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game
Study NCT00154687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin, 5-Fluorouracil
Study NCT03618199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efficacy of transcranial vibrating system on mitigating dizziness and nausea during caloric testing
Description: Transcranial vibrating system will be on then off (or off then on in a random order) during a repeated application of the calorics testingstimulus, i.e. warm or cold water irrigated in the left (then right) ear canal. The effect of the vibrating system on 1) resulting dizziness and nausea often experienced by patients and 2) clinical parameters measured by caloric testing will be quantified.
Study NCT02461004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391
Description: Investigational product is prescribed to all of radomized subjects for two times.
Study NCT02461004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovastatin and Ezetimibe combination therapy
Description: Investigational products are prescribed to all of radomized subjects for two times.
Study NCT01428427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
Study NCT01428427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
Study NCT02708381 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: Screening for geriatric issues to be referred to the Moffitt Cancer Center Oncogeriatric Information Team (OGIT).
Study NCT01823705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exilis Implantable Gastric Electrical Stimulation (GES)
Study NCT02952521 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: CA125 and ctDNA
Study NCT02952521 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Tissue Biopsy
Description: Only collected at time of surgery if patient undergoes surgical debulking
Study NCT00505154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 10 mg tablets od for 6 months
Study NCT00505154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03766776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib capsules: dosage of 12 mg PO qd, 14 days, 7 days, 21 days for a cycle. The dosage was adjusted according to the adverse reactions of patients.
Study NCT04477395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: SRP will be supplemented with the dietary fish oil rich in omega-3 PUFAs EPA and DHA for 6 months. Fish oil (BioMarine Medical, 200 ml liquid), obtained from Tasmanian deep sea shark and Norwegian cod liver and sardine, anchovy and mackerel muscle, will be administered two times a day at a dose 10 ml. Daily dose of 20 ml provides 2.6 g of EPA and 1.8 g of DHA.
Study NCT04477395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP only
Description: Scaling and root planing will be the only method of treatment.
Study NCT04477395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP only
Description: Scaling and root planing will be the only method of treatment.
Study NCT00441259 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax™-JE
Description: One dose of 4.0 log10 PFU is given in a volume of 1 ml for children aged > 3 years and 0.5 ml to children and infants aged \< 3 years administered subcutaneously
Study NCT00441259 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis Inactivated Mouse Brain Vaccine
Description: Two doses of 1 ml reconstituted JE-MBDV is given to subjects aged > 3 years and 0.5 ml is given to children and infants aged \< 3 years administered subcutaneously
Study NCT01098916 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Home X-rays
Description: X-rays examinations performed at home
Study NCT01098916 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: X-rays in hospital
Study NCT01162486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin & midazolam
Description: rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study NCT01162486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine & midazolam
Description: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study NCT01162486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine & midazolam
Description: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study NCT01162486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine & midazolam
Description: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study NCT01162486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine and midazolam
Description: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study NCT01162486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine and midazolam
Description: rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study NCT01305408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil tablets, taken orally, once daily in the morning
Study NCT01305408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, taken orally, once daily in the morning
Study NCT03513705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best practices in pancreatic cancer care
Description: All best practices follow the current state of the Dutch guideline on pancreatic cancer and the literature.
Study NCT04439045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: VPM1002 is a recombinant BCG (rBCG)
Study NCT04439045 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study NCT02700360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-fat diet
Description: This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900\~1,000 kcal, contains 50\~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects.